Actively Recruiting
Observational Study of Platelet Dysfunction Assessed by Thromboelastography in Cardiovascular Surgery (DISPLATEG)
Led by Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · Updated on 2025-08-08
180
Participants Needed
1
Research Sites
82 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Perioperative bleeding requiring blood transfusion is common during cardiovascular surgery, especially in procedures requiring cardiopulmonary bypass. Adenosine diphosphate (ADP) plays a fundamental role in platelet function. Several studies have shown that some patients not receiving antiplatelet therapy undergoing cardiovascular surgery have decreased platelet ADP receptor activity; the prevalence of this condition can be as high as 36%. Furthermore, extracorporeal circulation itself has been shown to cause a reduction in platelet function. Platelet dysfunction due to reduced platelet receptor activity after cardiac surgery is potentially a common cause of bleeding, perioperative blood transfusion, and surgical reexploration in patients not receiving antiplatelet agents. However, these studies are conducted with few patients and present some contradictory results, so the evidence is still scarce. The study hypothesis is that preoperative platelet dysfunction for ADP measured by TEG® Platelet Mapping™ is associated with a higher incidence of moderate-severe bleeding after CPB in patients undergoing cardiovascular surgery.
CONDITIONS
Official Title
Observational Study of Platelet Dysfunction Assessed by Thromboelastography in Cardiovascular Surgery (DISPLATEG)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Over 18 years of age
- Undergoing elective surgery using cardiopulmonary bypass (CPB)
- Able to understand the study and sign informed consent
- ASA physical status classification I to IV
- Normal preoperative coagulation tests and platelet count
- Sufficient intellectual capacity to understand the procedure
You will not qualify if you...
- Not meeting the inclusion criteria
- Recent use of antiplatelet agents without proper washout (5 days for clopidogrel and ticagrelor, 7 days for prasugrel)
- Recent use of anticoagulants without proper washout
- Platelet count below 100,000 or anemia with hemoglobin less than 11 g/dL
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Salamanca University Hospital
Salamanca, Spain, 37007
Actively Recruiting
Research Team
J
José A. Sastre
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here